PMID- 21573959
OWN - NLM
STAT- MEDLINE
DCOM- 20121029
LR  - 20220331
IS  - 1573-0646 (Electronic)
IS  - 0167-6997 (Linking)
VI  - 30
IP  - 4
DP  - 2012 Aug
TI  - Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.
PG  - 1791-801
LID - 10.1007/s10637-011-9677-6 [doi]
AB  - Several angiogenic mechanisms are involved in the pathology of renal cell 
      carcinoma (RCC). Increasing knowledge of angiogenesis and the associated 
      signalling pathways has led to the development of targeted antiangiogenic agents 
      for the treatment of metastatic RCC and the introduction of these agents has 
      significantly improved outcomes for these patients. This article provides an 
      overview of the angiogenic mechanisms implicated in RCC, focusing on the main 
      vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) 
      and mammalian target of rapamycin (mTOR) signalling pathways. Targeted 
      antiangiogenic agents for the treatment of mRCC include receptor tyrosine kinase 
      inhibitors (such as sunitinib, sorafenib, pazopanib, axitinib, cediranib and 
      tivozanib), monoclonal antibodies (such as bevacizumab) and mTOR inhibitors (such 
      as temsirolimus and everolimus). In this article, we consider the modes of action 
      of these targeted agents and their differing target receptor profiles and we also 
      evaluate how these correlate with their clinical efficacy and tolerability 
      profiles.
FAU - Negrier, Sylvie
AU  - Negrier S
AD  - Universite de Lyon-Centre Leon Berard, 28 rue Laennec, 69373 Lyon cedex 08, 
      France. negrier@lyon.fnclcc.fr
FAU - Raymond, Eric
AU  - Raymond E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20110515
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Angiogenesis Inhibitors)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects/*pharmacology/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Models, Biological
MH  - Neoplasm Metastasis
MH  - Practice Patterns, Physicians'
EDAT- 2011/05/17 06:00
MHDA- 2012/10/30 06:00
CRDT- 2011/05/17 06:00
PHST- 2011/03/04 00:00 [received]
PHST- 2011/04/26 00:00 [accepted]
PHST- 2011/05/17 06:00 [entrez]
PHST- 2011/05/17 06:00 [pubmed]
PHST- 2012/10/30 06:00 [medline]
AID - 10.1007/s10637-011-9677-6 [doi]
PST - ppublish
SO  - Invest New Drugs. 2012 Aug;30(4):1791-801. doi: 10.1007/s10637-011-9677-6. Epub 
      2011 May 15.